Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. The short people have departed for their respective destinations — the local schoolhouse and gainful employment — which leaves us alone with the official mascots in our respective corners. All of which means the time has come to get cracking. On that note, here are a few items of interest to help you along. Hope you have a smashing day and do keep us in mind if anything interesting arises …

Novo Nordisk (NOV) will cut 400 R&D jobs from Denmark and China in order to shift investment toward “biological and technological innovation.” The drug maker, which employs more than 42,000 people globally, has encountered pricing pressures, especially on its key diabetes franchise in the U.S. “Our analysis shows that we have a surplus of manual labor and are lacking competences in the digital sphere, informatics, data science, artificial intelligence and automations,” Novo Nordisk chief science officer Mads Krogsgaard Thomsen tells Reuters.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy